Unpacking the Latest Options Trading Trends in Amgen
Unpacking the Latest Options Trading Trends in Amgen
Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
財力雄厚的投資者對安進（納斯達克股票代碼：AMGN）採取了看跌的態度，這是市場參與者不容忽視的。我們對本辛加公開期權記錄的追蹤今天揭示了這一重大舉措。這些投資者的身份仍然未知，但是AMGN的如此重大變動通常表明即將發生重大事件。
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
我們今天從觀察中收集了這些信息，當時Benzinga的期權掃描儀重點介紹了安進的8項非同尋常的期權活動。這種活動水平與衆不同。
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 6 are puts, totaling $287,160, and 2 are calls, amounting to $67,000.
這些重量級投資者的總體情緒存在分歧，37％的人傾向於看漲，62％的人傾向於看跌。在這些值得注意的期權中，有6個是看跌期權，總額爲287,160美元，2個是看漲期權，總額爲67,000美元。
Projected Price Targets
預計價格目標
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $315.0 and $355.0 for Amgen, spanning the last three months.
在評估了交易量和未平倉合約之後，很明顯，主要市場推動者將注意力集中在安進過去三個月的315.0美元至355.0美元之間的價格區間上。
Volume & Open Interest Trends
交易量和未平倉合約趨勢
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
查看交易量和未平倉合約是一種對股票進行盡職調查的有見地的方法。
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
這些數據可以幫助您跟蹤給定行使價下安進期權的流動性和利息。
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $315.0 to $355.0 in the last 30 days.
下面，我們可以分別觀察安進所有鯨魚活動的看漲期權和未平倉合約在過去30天內在315.0美元至355.0美元範圍內的變化。
Amgen Option Activity Analysis: Last 30 Days
安進期權活動分析：過去 30 天
Noteworthy Options Activity:
值得注意的期權活動：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | PUT | SWEEP | BEARISH | 10/18/24 | $12.5 | $12.4 | $12.5 | $325.00 | $67.4K | 789 | 98 |
| AMGN | PUT | TRADE | BEARISH | 01/16/26 | $31.75 | $30.3 | $31.75 | $320.00 | $63.5K | 162 | 25 |
| AMGN | PUT | TRADE | BEARISH | 03/21/25 | $30.55 | $30.5 | $30.55 | $340.00 | $61.1K | 2 | 20 |
| AMGN | PUT | TRADE | BEARISH | 10/18/24 | $14.45 | $14.45 | $14.45 | $330.00 | $36.1K | 253 | 50 |
| AMGN | CALL | SWEEP | BULLISH | 08/09/24 | $3.45 | $2.57 | $3.45 | $355.00 | $34.5K | 16 | 100 |
| 符號 | 看跌/看漲 | 交易類型 | 情緒 | Exp。日期 | 問 | 出價 | 價格 | 行使價 | 總交易價格 | 未平倉合約 | 音量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 放 | 掃 | 粗魯的 | 10/18/24 | 12.5 美元 | 12.4 美元 | 12.5 美元 | 325.00 美元 | 67.4 萬美元 | 789 | 98 |
| AMGN | 放 | 貿易 | 粗魯的 | 01/16/26 | 31.75 美元 | 30.3 美元 | 31.75 美元 | 320.00 美元 | 63.5 萬美元 | 162 | 25 |
| AMGN | 放 | 貿易 | 粗魯的 | 03/21/25 | 30.55 美元 | 30.5 美元 | 30.55 美元 | 340.00 美元 | 61.1 萬美元 | 2 | 20 |
| AMGN | 放 | 貿易 | 粗魯的 | 10/18/24 | 14.45 美元 | 14.45 美元 | 14.45 美元 | 330.00 美元 | 36.1 萬美元 | 253 | 50 |
| AMGN | 打電話 | 掃 | 看漲 | 08/09/24 | 3.45 美元 | 2.57 美元 | 3.45 美元 | 355.00 美元 | 34.5 萬美元 | 16 | 100 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是基於生物技術的人體療法的領導者。旗艦藥物包括紅細胞增強劑Epogen和Aranesp、免疫系統增強劑Neupogen和Neulasta以及治療炎症性疾病的Enbrel和Otezla。安進於2006年推出了其首款癌症療法Vectibix，並銷售強化骨骼的藥物Prolia/Xgeva（2010年獲得批准）和Evenity（2019年）。對Onyx的收購加強了該公司與Kyprolis合作的治療腫瘤學產品組合。最近推出的產品包括Repatha（降膽固醇）、Aimovig（偏頭痛）、Lumakras（肺癌）和Tezspire（哮喘）。2023年Horizon的收購帶來了幾種罕見疾病藥物，包括甲狀腺眼病藥物Tepezza。安進的生物仿製藥產品組合也在不斷增長。
Current Position of Amgen
安進的現狀
- Currently trading with a volume of 164,369, the AMGN's price is down by -0.04%, now at $334.17.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 11 days.
- AMGN目前的交易量爲164,369美元，價格下跌了-0.04％，目前爲334.17美元。
- RSI讀數表明該股目前可能處於超買狀態。
- 預計收益將在11天后發佈。
Expert Opinions on Amgen
關於安進的專家意見
2 market experts have recently issued ratings for this stock, with a consensus target price of $321.5.
2位市場專家最近發佈了該股的評級，共識目標價爲321.5美元。
- An analyst from Argus Research has decided to maintain their Buy rating on Amgen, which currently sits at a price target of $340.
- An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Amgen, which currently sits at a price target of $303.
- 阿格斯研究的一位分析師已決定維持對安進的買入評級，目前的目標股價爲340美元。
- 摩根士丹利的一位分析師已決定維持對安進的等權評級，安進目前的目標股價爲303美元。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
與僅交易股票相比，期權是一種風險更高的資產，但它們具有更高的獲利潛力。嚴肅的期權交易者通過每天自我教育、擴大交易規模、關注多個指標以及密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。